Insulinoma is the most common neuroendocrine tumor of the pancreas. Its incidence is 1-4/million/year (1, 2) and it accounts for almost 1-2% of all diagnosed neoplasms of this organ (3) . These tumors are most commonly single (90%), benign (90%) focal lesions (more than 90%) and can be found in patients at any age, but are more common in females (4) .
The insulinoma is characterized by hyperinsulinemia accompanied by hypoglycemia and signs and symptoms resolving upon glucose administration (Whipple's triad). The
RESULTS
Between 2007 and 2013, 530 patients underwent surgical treatment at the Department for the tumor of the pancreas. Table 1 presents spectrum of performed surgical procedures and histopathological diagnoses of the operated tumors. Insulinomas were found in 10 patients (accounting for 1.88% of all operated tumors of the pancreas). Signs and symptoms of hypoglycemia were found in all these cases in the preoperative period. Signs and symptoms resulting from paroxysmal hypoglycemia did not resolve postoperatively in one patient who presented with preoperative signs and symptoms of insulinoma. The final histopathological examination demonstrated hyperplasia of pancreatic ß-cells (nesidioblastosis) in this patient. All insulinomas were benign. Table 2 presents data on patients with pancreatic insulinomas who underwent surgical treatment. Results of preoperative imaging studies (ultrasound, CT and MRI of the pancreas, EUS) were verified by the intraoperative ultrasound imaging that in each case confirmed localization of the tumor. An average age of patients who underwent surgical treatment was 47.5±13.8 years. An average size of the tumor was 1.6±0.5 cm. Six patients underwent extirpation of the insulinoma, while the other patients underwent distal resection of the pancreas. All patients underwent "an open surgical procedure". The average duration of the surgical procedure was 55±45 minutes. Duration of the hospitalization in the analyzed group of patients was 7±5 days. Incidence of postoperative pancreatic fistulas was 10%. All insulinomas were benign. In the postoperative period one patients developed pancreatic fistula that required reoperation involving Roux-en-Y pancreaticojejunostomy; furthermore infection of postoperative wound, treated medically, occurred in two patients.
DISCUSSION
Tumors of the pancreas constitute a heterogeneous group of focal lesions, involving both exo-and endocrine neoplasms as well as inflammatory tumors. This was reflected by the patient population who underwent surgical treatment at our Department (tab. 1) principal provocation tests used currently in the diagnostic workup of these tumors include hunger test and exercise test (5) . The differential diagnosis of insulinoma should include hyperplasia of pancreatic islets (nesidioblastosis) (6), other neuroendocrine tumors that also secrete insulin and extrapancreatic causes of hypoglycemia (7) . Due to small size of insulinomas (more than 90% of tumors are smaller than 2 cm) (8) their diagnosis based on imaging studies (ultrasound and contrastenhanced CT imaging of abdominal cavity, MRI of the pancreas) can be challenging. Endoscopic ultrasound is the best method of preoperative assessment of such lesions (9) . Intraoperative palpation of the pancreas is also an accepted method of localization of a tumor, resulting in its detection in 42 to 95% of cases (4) . Intraoperative ultrasound imaging is the most sensitive method of insulinoma localization, resulting in its detection in 75 to 100% of cases (10) . This modality also identifies the pancreatic duct, which allows for safe extirpation of the tumor with minimization of the risk of postoperative pancreatic fistula.
A surgical procedure is the gold standard treatment of insulinomas, resulting in curing of almost 95% of patients. The surgical treatment, depending on clinical situation, involves extirpation of the tumor, distal resection of the pancreas, duodenopancreatectomy (Whipple procedure) or complete resection of the pancreas (11).
The (12-15). Preoperative differentiation of pancreatic tumors is difficult, and impossible in many cases. Due to these difficulties, questions are emerging with regard to optimal management of patients with accidentally discovered pancreatic incidentalomas. In view of the fact that the vast majority of these lesions are malignant or potentially malignant (tab. 1), radical excision of such lesions continues to be the first choice treatment in these patients (15).
A surgical procedure is also indicated in all localized insulinomas of the pancreas. The choice of surgical procedure depends on the tumor size and location. Due to most commonly benign nature of these lesions, pancreas sparing procedures are preferred, such as tumor extirpation o limited resection of the pancreas that allow for minimization of the risk of postoperative exo-or endocrine pancreatic insufficiency. With the tumor extirpation, various techniques are used to minimize the risk of postoperative fistula of the pancreas. With small tumors, usually the pancreatic parenchyma is sutured. However, concurrent Roux-en-Y pancreaticojejunostomy should be considered in any case of suspected intraoperative injury of the pancreatic duct.
Among the study group there was a single case of nesidioblastosis, which is a well known pathology involving permanent hyperinsulinemia in infants; however, nesidioblastosis is rare in adults. So far only 71 cases of nesidioblastosis have been reported in adults (16). Low incidence of this disease hampers preparation of clear diagnostic criteria that would allow for proper preoperative diagnosis to be made. The diagnostic and therapeutic management in the event of endogenous hyperinsulinemia with hypoglycemia continues to involve a combination of biochemical tests, imaging studies, intraoperative examination and histopathological assessment of the excised specimen. However, identification and extirpation of an insulinoma does not rule out coexistence of nesidioblastosis. In such cases monitoring of insulin concentration in the portal vein and peripheral blood collected at the beginning of the procedure and 20 minutes after excision of the tumor may be helpful. Reduction of insulin concentration to normal values and insulin/glucose ratio to below 0.4 indicates successful surgical treatment (16). If attempts of intraoperative localization of the tumor are unsuccessful and biochemical tests do not demonstrate reduction of insulin concentration, "blind" distal resection of the pancreas used to be recommended. However, due to high risk of development of diabetes mellitus, currently such procedures are rarely conducted (17) .
Concurrently diagnostic workup and treatment of such patients should be conducted at centers that are experienced in the treatment of insulinomas. Further advanced imaging studies under the guidance of an experienced endocrinologist are advised rather than "blind" resection of the pancreas. Furthermore, a surgeon who undertakes the treatment of a patient with insulinoma should be highly experienced in interpretation of imaging studies and in surgical techniques involving the pancreas.
One patient with pancreatic insulinoma experienced preoperative symptoms of neuroglycopenia: she had seizures. Seizures were misdiagnosed as epilepsy. Her complaints resolved after extirpation of the insulinoma and her antiepileptic therapy as discontinued. This indicates that the key component of the diagnostic workup of the cases of loss of consciousness and seizures is detailed history with regard to premonitory symptoms (18) . Erroneous diagnosis of causes of loss of consciousness can carry serious soncequences, including patient's death (19) .
Recently there have been multiple reports documenting laparoscopic resections of the pancreas (20, 21, 22) . However, studies that compared laparoscopic procedures and "open" approaches usually involved small groups of patients and their results are equivocal. Open resections of the pancreas continue to be a preferred method of surgical treatment of patients with a tumor of the pancreas, accounting for close to 90% of all procedures (23). This also applies to insulinomas that have uncharacteristic presentation and their identification during a laparoscopic procedure, when palpation is impossible, is difficult. In such cases laparoscopic ultrasound may be helpful, allowing for localization of the tumor and assessment of its location relative to adjacent blood vessels and pancreatic duct (24) . However due to high cost, such equipment is still poorly available in our country. Analysis of the clinical data revealed that duration of patient hospitalization after laparoscopic resections of the pancreas due to insulinomas was 2 to 14 days (in our group of patients who underwent "an open procedure" the average duration of hospitalization was similar, 7±5 days). An average duration of the procedure is markedly longer for laparoscopic procedures, from 1.7 to 5 hours (it was 55±45 minutes in our group of patients). Incidence of fistula formation is comparable for laparoscopic and "open" procedures, from 0 to almost 40% (this rate was 10% in our group of patients) (4) .
In view of this high risk of pancreatic fistula, many authors believe that a drain should be placed in abdominal cavity after each surgical resection of pancreatic insulinoma. This drain allows for monitoring and early diagnosis of leakage of the pancreatic juice in the postoperative period. Furthermore, previously published data indicated that the conversion rate in laparoscopic resections of the pancreas was high, sometimes as high as 40%; as with other procedures, it largely depended on experience of a surgeon and on the learning curve (4). Obviously lower postoperative pain intensity and quicker return to daily activities are clear advantages of laparoscopic resections of the pancreas. However, due to lack of multicenter studies assessing utility of laparoscopic techniques in resections of the pancreas for insulinomas, an open approach was used in all surgical procedures performed at our Department.
All insulinomas operated at our Department were benign. However, insulinomas can also be malignant (4 to 14% of cases) (25). In such cases aggressive treatment, involving extensive resection of the pancreas, liver resection or transplantation, chemoembolization or radiofrequency ablation, is recommended. Diazoxide, a hyperglycemic agent that inhibits insulin secretion, and somastatin analogs that inhibit secretion of gastrointestinal hormones, are recommended for patients with unresectable insulinomas. Detection of remote metastases and progression of the tumor size are indications for chemotherapy. Streptozotocin with 5-fluorouracyl are the most commonly used regimen. Chemotherapy results in complete cure in as many as 20% of cases (26).
CONCLUSIONS
Insulinomas were rare, benign tumors and their treatment was usually unproblematic in patients who underwent surgical treatment at our Department. However, there is a small group of cases that can be associated with problematic clinical situations such as diagnostic problems with the tumor localization or coexisting nesidioblastosis. Due to this fact, diagnostic workup and treatment of patients with insulinomas should be conducted at specialist centers. Correct diagnostic and therapeutic management, involving close cooperation between multiple medical specialists, results in complete curing of majority of patients with a small incidence of postoperative complications.
